$Immutep (IMMP.US)$ Immutep (ASX:IMM) said the phase 1 INSIGHT-003 trial reached an enrollment target of about 50 patients across Germany, according to a Monday Australian bourse filing.
INSIGHT-003 is an investigator-initiated study led by the Frankfurt Institute of Clinical Cancer Research IKF evaluating a triple combination therapy in first-line non-small cell lung cancer patients.
It is testing eftilagimod alpha in combination with antiPD-1 therapy, pembrolizumab, and doublet chemotherapy as a potential first-line treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer.
The biotechnology firm said that the first overall survival results, issued on Nov. 14, 2024, from the trial showed mature data in patients with a minimum follow-up of 22 months achieved a median overall survival of 32.9 months and a 24-month overall survival rate of 81%.
The company's shares rose past 1% in recent Monday trade.